In the last trading session, 4.17 million shares of the ImmunityBio Inc (NASDAQ:IBRX) were traded, and its beta was 0.70. Most recently the company’s share price was $3.36, and it changed around $0.05 or 1.51% from the last close, which brings the market valuation of the company to $2.45B. IBRX currently trades at a discount to its 52-week high of $10.53, offering almost -213.39% off that amount. The share price’s 52-week low was $2.28, which indicates that the current value has risen by an impressive 32.14% since then. We note from ImmunityBio Inc’s average daily trading volume that its 10-day average is 5.69 million shares, with the 3-month average coming to 5.94 million.
ImmunityBio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended IBRX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. ImmunityBio Inc is expected to report earnings per share of -0.13 for the current quarter.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Instantly IBRX has showed a green trend with a performance of 1.51% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.46 on recent trading dayincreased the stock’s daily price by 2.89%. The company’s shares are currently up 31.25% year-to-date, but still down -2.61% over the last five days. On the other hand, ImmunityBio Inc (NASDAQ:IBRX) is 23.08% up in the 30-day period. We can see from the shorts that 54.54 million shares have been sold at a short interest cover period of 9.56 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 44.0% from its current value. Analyst projections state that IBRX is forecast to be at a low of $6 and a high of $6.
ImmunityBio Inc (IBRX) estimates and forecasts
The year-over-year growth rate is expected to be 3,312.86%, up from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 9.51M in revenue for the current quarter. 2 analysts expect ImmunityBio Inc to make 23.09M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 139k and 40k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 6,738.31%. Forecasts for the next quarter put sales growth at 57,618.75%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 1.17%. ImmunityBio Inc earnings are expected to increase by 30.43% in 2025, but the outlook is positive 32.58% per year for the next five years.
IBRX Dividends
ImmunityBio Inc’s next quarterly earnings report is expected to be released in March.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 73.52% of ImmunityBio Inc shares, and 9.86% of them are in the hands of institutional investors. The stock currently has a share float of 37.24%. ImmunityBio Inc stock is held by 263.0 institutions, with VANGUARD GROUP INC being the largest institutional investor. By 2024-06-30, it held 2.0558% of the shares, which is about 13.83 million shares worth $87.42 million.
BLACKROCK INC., with 1.6978% or 11.42 million shares worth $72.19 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF were the top two Mutual Funds as of Sep 30, 2024 . The former held 5.72 shares worth $19.22 million, making up 0.82% of all outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held roughly 4.98 shares worth around $16.72 million, which represents about 0.71% of the total shares outstanding.
